News

Best Life on MSN23h
Ozempic and Wegovy May Have Landed 25,000 People in the ER—Here's the Scary Reason Why
Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.
The top reasons Ozempic users are going to the hospital — and the ‘Wild West’ factor that could be driving an unexpected issue
Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...
Healio2d
Semaglutide tied to significant improvements in MASH, liver fibrosis at 72 weeks
Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...
Weight-Loss Drugs Have Sent a Shocking Number of People to the Emergency Room, New Study Claims
Researchers believe nearly 25,000 hospital visits occurred, mostly due to gastrointestinal complications A new study analyzed ...
Applied Clinical Trials Online1d
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
Managed Healthcare Executive1d
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
Semaglutide Shows Major Promise for Treating Serious Liver Disease
Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.
Fierce Pharma1d
Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...